首页> 外文期刊>Malaria Journal >Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene
【24h】

Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene

机译:chabaudi chabaudi疟原虫疟原虫可以对atovaquone产生稳定的抗性,并带有细胞色素b基因突变

获取原文
获取外文期刊封面目录资料

摘要

Background Plasmodium falciparum, has developed resistance to many of the drugs in use. The recommended treatment policy is now to use drug combinations. The atovaquone-proguanil (AP) drug combination, is one of the treatment and prophylaxis options. Atovaquone (ATQ) exerts its action by inhibiting plasmodial mitochondria electron transport at the level of the cytochrome bc1 complex. Plasmodium falciparum in vitro resistance to ATQ has been associated with specific point mutations in the region spanning codons 271-284 of the cytochrome b gene. ATQ -resistant Plasmodium yoelii and Plasmodium berghei lines have been obtained and resistant lines have amino acid mutations in their CYT b protein sequences. Plasmodium chabaudi model for studying drug-responses and drug-resistance selection is a very useful rodent malaria model but no ATQ resistant parasites have been reported so far. The aim of this study was to determine the ATQ sensitivity of the P. chabaudi clones, to select a resistant parasite line and to perform genotypic characterization of the cytb gene of these clones. Methods To select for ATQ resistance, Plasmodium. chabaudi chabaudi clones were exposed to gradually increasing concentrations of ATQ during several consecutive passages in mice. Plasmodium chabaudi cytb gene was amplified and sequenced. Results ATQ resistance was selected from the clone AS-3CQ. In order to confirm whether an heritable genetic mutation underlies the response of AS-ATQ to ATQ, the stability of the drug resistance phenotype in this clone was evaluated by measuring drug responses after (i) multiple blood passages in the absence of the drug, (ii) freeze/thawing of parasites in liquid nitrogen and (iii) transmission through a mosquito host, Anopheles stephensi. ATQ resistance phenotype of the drug-selected parasite clone kept unaltered. Therefore, ATQ resistance in clone AS-ATQ is genetically encoded. The Minimum Curative Dose of AS-ATQ showed a six-fold increase in MCD to ATQ relative to AS-3CQ. Conclusions A mutation was found on the P. chabaudi cytb gene from the AS-ATQ sample a substitution at the residue Tyr268 for an Asn, this mutation is homologous to the one found in P. falciparum isolates resistant to ATQ.
机译:背景恶性疟原虫已对使用中的许多药物产生耐药性。现在建议的治疗策略是使用药物组合。 Atovaquone-Proguanil(AP)药物组合是治疗和预防选择之一。 Atovaquone(ATQ)通过抑制细胞色素bc1复合体水平上的线粒体线粒体电子传递发挥其作用。恶性疟原虫对ATQ的体外抗性与细胞色素b基因密码子271-284区域中的特定点突变有关。已经获得了ATQ抗性的约氏疟原虫和伯氏疟原虫系,并且抗性系在它们的CYT b蛋白序列中具有氨基酸突变。 Chabaudi疟原虫模型用于研究药物反应和药物耐药性选择是一种非常有用的啮齿动物疟疾模型,但迄今为止尚未报道过ATQ耐药性寄生虫。这项研究的目的是确定伪装chapaudi克隆的ATQ敏感性,选择抗性寄生虫品系,并对这些克隆的cytb基因进行基因型鉴定。方法选择耐ATQ的疟原虫。 chabaudi chabaudi克隆在小鼠连续数次传代过程中暴露于逐渐增加的ATQ浓度。 Chabaudi cytb疟原虫基因被扩增和测序。结果ATQ抗性选自克隆AS-3CQ。为了确认可遗传性突变是否是AS-ATQ对ATQ应答的基础,通过测量(i)在不存在药物的情况下经过多次血液传代后的药物应答,评估了该克隆中耐药性表型的稳定性,( ii)冷冻/解冻液氮中的寄生虫,以及(iii)通过蚊子寄主按蚊传播。药物选择的寄生虫克隆的ATQ抗性表型保持不变。因此,克隆AS-ATQ中的ATQ抗性是遗传编码的。 AS-ATQ的最低治疗剂量显示,相对于AS-3CQ,MCD相对于ATQ增长了六倍。结论从AS-ATQ样品的chabaudi cytb基因上发现了一个突变,在Tyr268残基上取代了Asn,该突变与在对ATQ有抗性的恶性疟原虫中发现的突变同源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号